stockrow
Saturday 7 November 2026
Export NGNE’s income statement to Excel — free account
Neurogene Inc.
NGNE Healthcare Biotechnology
Neurogene Inc.’s revenue for fiscal 2024 (year ended December 2024) was $925,000.00.
- EPS
- −45.7%
- Free cash flow
- −23.0%
- Total debt
- −66.7%
Quarter to June 2026, against a year earlier
25.29
0.36
−1.40%
Follow NGNE
Alert me
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | — | 0.00 | — | — | — | — | — | 0.00 | — |
Altman Z-Score |
— | — | 2.07 | — | — | — | — | — | 8.68 | — |
P/S ratio |
— | — | 0.00 | — | — | — | — | — | 0.00 | — |
P/FCF ratio |
— | — | 0.00 | — | — | — | — | — | 0.00 | — |
Altman Z″-Score (non-manufacturers) |
— | — | 9.07 | — | — | — | — | — | 14.53 | — |
P/Operating CF |
— | — | (5.20) | — | — | — | — | — | (22.95) | — |
P/B ratio |
— | — | 0.70 | — | — | — | — | — | 1.29 | — |
Price to Tangible BV |
— | — | 0.70 | — | — | — | — | — | 1.29 | — |
EV/Sales |
— | — | 0.00 | — | — | — | — | — | 0.00 | — |
EV/EBITDA |
— | — | 0.80 | — | — | — | — | — | 0.00 | — |
EV/Operating CF |
— | — | 0.83 | — | — | — | — | — | (1.26) | — |
EV/FCF |
— | — | 0.83 | — | — | — | — | — | (1.25) | — |
Quick Ratio |
10.87 | 9.93 | 16.68 | 30.17 | 24.41 | 16.50 | 12.33 | 8.58 | 20.61 | 16.39 |
Current Ratio |
10.87 | 9.93 | 16.68 | 30.28 | 24.66 | 16.67 | 12.74 | 8.72 | 20.84 | 16.56 |
Net Debt/EBITDA |
2.74 | 2.13 | 2.38 | 2.03 | 6.03 | 2.44 | 1.54 | 3.76 | 3.82 | 2.57 |
Debt/Assets |
0.03% | 0.03% | 0.01% | 0.10% | 0.05% | 0.04% | 0.06% | 0.03% | 0.01% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.27 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.82 | 0.89 | 1.00 | 0.22 | 0.74 | 0.78 | 0.96 | 1.42 | 0.94 | 0.85 |
Capex/Depreciation |
0.00 | (1.37) | (0.17) | (1.66) | (1.22) | (1.43) | (0.70) | (0.10) | (0.98) | 0.82 |
Interest Coverage |
(37,645.00) | (12,779.75) | (8,156.00) | (46.02) | (68.83) | (3,194.63) | (28,258.50) | (4,631.92) | (6,883.75) | (20,665.60) |
| (29.24%) | (41.21%) | (36.82%) | (64.79%) | (19.99%) | (36.33%) | 3,839.23% | (180.30%) | (30.28%) | (31.41%) | |
| (27.64%) | (37.92%) | (33.61%) | (61.82%) | (18.61%) | (32.47%) | (40.50%) | (21.89%) | (26.92%) | (28.94%) | |
ROIC |
(56.49%) | 0.00% | 0.00% | 0.00% | 0.00% | (8,175.92%) | (211.87%) | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(39.03%) | (50.81%) | (43.30%) | (49.28%) | (17.50%) | (42.80%) | (56.21%) | (18.67%) | (23.77%) | (33.69%) |
Average Days of Receivables |
0.00 | 0.00 | 3.46 | 0.00 | — | — | — | — | 0.00 | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 167.16% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 6,585.62% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 63.34% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 2,444.65% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 18.79% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 899.46% | 0.00% |
Graham Net Nets |
— | — | 1.42 | — | — | — | — | — | 0.72 | — |
Graham Number |
— | — | 0.00 | — | — | — | — | — | 0.00 | — |
Earnings Yield |
— | — | (62.04%) | — | — | — | — | — | (18.68%) | — |
Free Cash Flow Yield |
— | — | (62.25%) | — | — | — | — | — | (17.78%) | — |
Revenue per Share |
0.00 | 0.00 | 21.26 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.05 | 0.00 |
Operating CF per Share |
(32.00) | (38.14) | (26.85) | (11.39) | (9.48) | (17.28) | (133.73) | (104.52) | (4.02) | (3.62) |
Capex per Share |
(0.75) | (0.42) | (0.04) | (0.65) | (0.86) | (1.19) | (5.65) | (0.65) | (0.05) | (0.06) |
Free Cash Flow per Share |
(32.75) | (38.56) | (26.89) | (12.04) | (10.34) | (18.47) | (139.38) | (105.17) | (4.07) | (3.67) |
Cash per Share |
109.09 | 92.18 | 65.42 | 105.88 | 74.31 | 51.77 | 207.65 | 400.73 | 17.78 | 12.61 |
Shareholders Equity per Share |
153.13 | 84.34 | 61.80 | 104.84 | 73.79 | 51.91 | 249.69 | 378.10 | 17.67 | 12.42 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
153.13 | 84.34 | 61.80 | 104.84 | 73.79 | 51.91 | 249.69 | 378.10 | 17.67 | 12.42 |
Free Cash Flow |
(30.94) | (45.21) | (31.63) | (16.27) | (26.79) | (50.82) | (55.05) | (51.74) | (71.41) | (78.36) |
Working Capital |
93.97 | 97.87 | 72.54 | 138.85 | 186.63 | 135.35 | 78.07 | 177.38 | 300.77 | 255.36 |
Capital Expenditures |
(0.71) | (0.49) | (0.05) | (0.88) | (2.22) | (3.26) | (2.23) | (0.32) | (0.81) | (1.18) |
Net Current Asset Value |
93.77 | 97.38 | 72.22 | 138.26 | 175.22 | 123.59 | 74.08 | 163.80 | 290.57 | 248.05 |
EV/EBIT |
— | — | 0.80 | — | — | — | — | — | 0.00 | — |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.87 | 0.00 |
Price to Operating Income |
— | — | 0.00 | — | — | — | — | — | 0.00 | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.00 | 0.40 | 0.72 | 0.26 | 0.51 | 0.35 | 0.16 | 0.19 | 0.05 | (0.11) |
Cash ROIC |
(12.49%) | (21.84%) | (21.14%) | (5.71%) | (6.98%) | (17.81%) | (30.46%) | (13.50%) | (11.47%) | (14.68%) |
Accounts Receivable Turnover |
0.00 | 0.00 | 51.18 | 0.00 | — | — | — | — | 0.00 | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Receivables |
0.37 | 0.58 | 0.49 | 0.37 | — | — | — | — | — | — |
Average Payables |
7.16 | 10.24 | 7.79 | 4.37 | 5.65 | 7.30 | 4.02 | 1.61 | 1.97 | 1.64 |
Average Assets |
133.86 | 132.35 | 93.97 | 112.32 | 178.77 | 186.89 | 136.26 | 165.92 | 279.15 | 312.17 |
Average Common Equity |
126.54 | 121.78 | 85.78 | 107.18 | 166.45 | 167.04 | (1.44) | 20.14 | 248.20 | 287.63 |
Columns are period end dates · fundamentals updated 26 Oct 2026